Transcription factors, the master regulators of gene expression, have long been deemed “undruggable” by the pharmaceutical industry due to their complex structures and historical challenges in targeting them effectively. However, advancements in technologies such as siRNA, omics, and AI/ML are now paving the way for a paradigm shift in how these pivotal genes can be harnessed for therapeutic purposes.
As these technologies mature, they are enabling a deeper understanding of transcription factors and their roles in diseases, including aging. The potential to reprogram cells back to a healthy state through the modulation of transcription factors could lead to a new category of drugs, significantly impacting the treatment landscape and potentially resulting in a wave of FDA approvals.
With the aging global population and increasing interest in addressing age-related diseases, the prospect of developing targeted therapies that leverage transcription factors could yield substantial benefits for patients worldwide. The convergence of siRNA delivery, expansive omics data, and advanced AI capabilities heralds a new era in drug development, suggesting that the once elusive goal of targeting transcription factors is now within reach.
Get started today with Solo access →
